Byline: Associated Press
WASHINGTON -- Millions of asthma sufferers are about to get a dramatically different treatment that promises to short-circuit some attacks: a drug named Xolair that won Food and Drug Administration approval late Friday.
It's only for patients with serious allergic asthma, where the breathing problems are triggered by allergies -- and then only if regular asthma medicines aren't working. And it requires monthly shots that will cost between $5,000 and $10,000 a year, depending on the dose.
But researchers say Xolair works differently than any other asthma medicine, blocking an allergic reaction well before it triggers …
No comments:
Post a Comment